TY - JOUR
T1 - The infant and toddler with wheezing
AU - Padem, Nurcicek
AU - Robison, Rachel Glick
N1 - Funding Information:
From the Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois Funded by the Ernest S. Bazley Grant to Northwestern Memorial Hospital and Northwestern University Rachel Glick Robison received funding from the National Heart, Lung, and Blood Institute for participation in AsthmaNet N. Padem has no conflicts of interest to declare pertaining to this article Address correspondence to Rachel Glick Robison, M.D., Box 60, 255 E. Chicago, Ave. Chicago, IL 60611 E-mail address: rrobison@luriechildrens.org Copyright © 2019, OceanSide Publications, Inc., U.S.A.
Publisher Copyright:
Copyright © 2019, OceanSide Publications, Inc., U.S.A.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Recurrent wheezing is common in young infants and toddlers, with 50% of all children having at least one wheezing episode in the first 6 years of life. Initial wheezing episodes in young children often are linked to respiratory infections due to viral pathogens, such as respiratory syncytial virus, human rhinovirus, human metapneumovirus, and influenza virus. Bacterial colonization of the neonatal airway also may be significant in the late development of recurrent wheeze and asthma. Wheezing in young children can be classified into specific phenotypes based on the onset and persistence of wheezing. Although some children will only wheeze transiently in early childhood, persistent wheezing is often classified as immunoglobulin E (IgE) associated and/or atopic or nonatopic. By using a modified asthma predictive index, future development of asthma can be interpreted, especially in high-risk populations. It is recommended to follow National Asthma Education and Prevention Program (NAEPP) guidelines for initiation of treatment; however, asthma management of young children often requires tailored regimens. Inhaled corticosteroids used as a daily controller medication have been shown to aid symptoms and exacerbation control; however, these do not change the natural course of the disease or progression to asthma. Although randomized double-blind studies in preschoolers investigated a role of macrolide antibiotics in early infection as well as high-dose inhaled corticosteroids during severe lower respiratory tract infections, more research is needed in this field to understand mechanisms of asthma development and optimal treatment in this young age group.
AB - Recurrent wheezing is common in young infants and toddlers, with 50% of all children having at least one wheezing episode in the first 6 years of life. Initial wheezing episodes in young children often are linked to respiratory infections due to viral pathogens, such as respiratory syncytial virus, human rhinovirus, human metapneumovirus, and influenza virus. Bacterial colonization of the neonatal airway also may be significant in the late development of recurrent wheeze and asthma. Wheezing in young children can be classified into specific phenotypes based on the onset and persistence of wheezing. Although some children will only wheeze transiently in early childhood, persistent wheezing is often classified as immunoglobulin E (IgE) associated and/or atopic or nonatopic. By using a modified asthma predictive index, future development of asthma can be interpreted, especially in high-risk populations. It is recommended to follow National Asthma Education and Prevention Program (NAEPP) guidelines for initiation of treatment; however, asthma management of young children often requires tailored regimens. Inhaled corticosteroids used as a daily controller medication have been shown to aid symptoms and exacerbation control; however, these do not change the natural course of the disease or progression to asthma. Although randomized double-blind studies in preschoolers investigated a role of macrolide antibiotics in early infection as well as high-dose inhaled corticosteroids during severe lower respiratory tract infections, more research is needed in this field to understand mechanisms of asthma development and optimal treatment in this young age group.
UR - http://www.scopus.com/inward/record.url?scp=85074742520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074742520&partnerID=8YFLogxK
U2 - 10.2500/aap.2019.40.4255
DO - 10.2500/aap.2019.40.4255
M3 - Article
C2 - 31690378
AN - SCOPUS:85074742520
SN - 1088-5412
VL - 40
SP - 393
EP - 395
JO - New England and regional allergy proceedings
JF - New England and regional allergy proceedings
IS - 6
ER -